S&P 500   4,349.93
DOW   34,168.09
QQQ   344.57
S&P 500   4,349.93
DOW   34,168.09
QQQ   344.57
S&P 500   4,349.93
DOW   34,168.09
QQQ   344.57
S&P 500   4,349.93
DOW   34,168.09
QQQ   344.57

RadNet Stock Forecast, Price & News

-0.27 (-1.10%)
(As of 01/26/2022 04:00 PM ET)
Today's Range
50-Day Range
52-Week Range
234,409 shs
Average Volume
239,253 shs
Market Capitalization
$1.30 billion
P/E Ratio
Dividend Yield
30 days | 90 days | 365 days | Advanced Chart
Receive RDNT News and Ratings via Email

Sign-up to receive the latest news and ratings for RadNet and its competitors with MarketBeat's FREE daily newsletter.

RadNet logo

About RadNet

RadNet, Inc. provides freestanding, fixed-site outpatient diagnostic imaging services in the United States. Its centers provide physicians with imaging capabilities to facilitate the diagnosis and treatment of diseases and disorders and reduce unnecessary invasive procedures. The firm offers magnetic resonance imaging, computed tomography, positron emission tomography, nuclear medicine, mammography, ultrasound, diagnostic radiology, fluoroscopy, and other related procedures. RadNet was founded by Howard G. Berger in 1980 and is headquartered in Los Angeles, CA.


RadNet (NASDAQ:RDNT) Stock Price Down 7%
January 25, 2022 |  americanbankingnews.com
$0.19 EPS Expected for RadNet, Inc. (NASDAQ:RDNT) This Quarter
January 11, 2022 |  americanbankingnews.com
Analysts Predict 18% Upside For SPSM - Nasdaq
December 24, 2021 |  nasdaq.com
See More Headlines

Industry, Sector and Symbol

Medical laboratories
Current Symbol
Year Founded

Sales & Book Value

Annual Sales
$1.07 billion
Cash Flow
$2.62 per share
Book Value
$5.00 per share


Net Income
$-14.84 million
Pretax Margin




Free Float
Market Cap
$1.30 billion

Company Calendar

Last Earnings
Next Earnings (Estimated)
Fiscal Year End

Social Links


Overall MarketRank

2.20 out of 5 stars

Medical Sector

401st out of 1,420 stocks

Medical Laboratories Industry

9th out of 31 stocks

Analyst Opinion: 3.3Community Rank: 4.5Dividend Strength: 0.0Insider Behavior: 2.5Valuation: 0.6 5 -4 -3 -2 -1 -

RadNet (NASDAQ:RDNT) Frequently Asked Questions

Is RadNet a buy right now?

3 Wall Street analysts have issued "buy," "hold," and "sell" ratings for RadNet in the last year. There are currently 1 hold rating and 2 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" RadNet stock.
View analyst ratings for RadNet
or view top-rated stocks.

How has RadNet's stock been impacted by Coronavirus (COVID-19)?

RadNet's stock was trading at $17.22 on March 11th, 2020 when Coronavirus (COVID-19) reached pandemic status according to the World Health Organization (WHO). Since then, RDNT stock has increased by 41.6% and is now trading at $24.38.
View which stocks have been most impacted by COVID-19

When is RadNet's next earnings date?

RadNet is scheduled to release its next quarterly earnings announcement on Monday, March 14th 2022.
View our earnings forecast for RadNet

How were RadNet's earnings last quarter?

RadNet, Inc. (NASDAQ:RDNT) announced its quarterly earnings data on Monday, November, 8th. The medical research company reported $0.21 earnings per share for the quarter, topping the consensus estimate of $0.18 by $0.03. The medical research company earned $332.70 million during the quarter, compared to analyst estimates of $341.26 million. RadNet had a net margin of 2.67% and a trailing twelve-month return on equity of 12.87%. RadNet's quarterly revenue was up 14.0% on a year-over-year basis. During the same period last year, the company earned $0.15 earnings per share.
View RadNet's earnings history

What guidance has RadNet issued on next quarter's earnings?

RadNet issued an update on its FY 2021 earnings guidance on Monday, December, 6th. The company provided earnings per share (EPS) guidance of for the period. The company issued revenue guidance of $1.30 billion-$1.35 billion, compared to the consensus revenue estimate of $1.34 billion.

What price target have analysts set for RDNT?

3 brokerages have issued twelve-month price objectives for RadNet's stock. Their forecasts range from $26.00 to $40.00. On average, they expect RadNet's stock price to reach $35.00 in the next year. This suggests a possible upside of 43.6% from the stock's current price.
View analysts' price targets for RadNet
or view top-rated stocks among Wall Street analysts.

Who are RadNet's key executives?

RadNet's management team includes the following people:
  • Howard G. Berger, Chairman, Co-President & Chief Executive Officer
  • Norman R. Hames, Co-President & COO-Western Operations (LinkedIn Profile)
  • Stephen M. Forthuber, Co-President & COO-Eastern Operations
  • Mark D. Stolper, Chief Financial Officer & Executive Vice President
  • John V. Crues, Medical Director & Vice President

What is Howard G. Berger's approval rating as RadNet's CEO?

174 employees have rated RadNet CEO Howard G. Berger on Glassdoor.com. Howard G. Berger has an approval rating of 45% among RadNet's employees. This puts Howard G. Berger in the bottom 10% of approval ratings compared to other CEOs of publicly-traded companies.

What other stocks do shareholders of RadNet own?

Based on aggregate information from My MarketBeat watchlists, some companies that other RadNet investors own include Advanced Micro Devices (AMD), AbbVie (ABBV), Inovio Pharmaceuticals (INO), NVIDIA (NVDA), OPKO Health (OPK), Boeing (BA), Rigel Pharmaceuticals (RIGL), UnitedHealth Group (UNH), Pfizer (PFE) and AT&T (T).

What is RadNet's stock symbol?

RadNet trades on the NASDAQ under the ticker symbol "RDNT."

Who are RadNet's major shareholders?

RadNet's stock is owned by a number of retail and institutional investors. Top institutional shareholders include Russell Investments Group Ltd. (0.44%), Cheyne Capital Management UK LLP (0.26%), State of Alaska Department of Revenue (0.06%), Brave Asset Management Inc. (0.02%) and Diversified Trust Co (0.02%). Company insiders that own RadNet stock include B Kaplan Survivor's Tru Karen, David L Swartz, John V Crues, Lawrence L Levitt, Lawrence L Levitt, Michael N Murdock, Norman R Hames and Ruth Louisa Villigerwilson.
View institutional ownership trends for RadNet

Which institutional investors are selling RadNet stock?

RDNT stock was sold by a variety of institutional investors in the last quarter, including Cheyne Capital Management UK LLP, Russell Investments Group Ltd., Brave Asset Management Inc., Diversified Trust Co, and State of Alaska Department of Revenue. Company insiders that have sold RadNet company stock in the last year include John V Crues, Lawrence L Levitt, Michael N Murdock, Norman R Hames, and Ruth Louisa Villigerwilson.
View insider buying and selling activity for RadNet
or view top insider-selling stocks.

How do I buy shares of RadNet?

Shares of RDNT can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is RadNet's stock price today?

One share of RDNT stock can currently be purchased for approximately $24.38.

How much money does RadNet make?

RadNet has a market capitalization of $1.30 billion and generates $1.07 billion in revenue each year. The medical research company earns $-14.84 million in net income (profit) each year or $0.64 on an earnings per share basis.

How many employees does RadNet have?

RadNet employs 8,327 workers across the globe.

When was RadNet founded?

RadNet was founded in 1980.

What is RadNet's official website?

The official website for RadNet is www.radnet.com.

Where are RadNet's headquarters?

RadNet is headquartered at 1510 COTNER AVE, LOS ANGELES CA, 90025.

How can I contact RadNet?

RadNet's mailing address is 1510 COTNER AVE, LOS ANGELES CA, 90025. The medical research company can be reached via phone at (310) 445-2800, via email at [email protected], or via fax at 310-445-2980.

This page was last updated on 1/27/2022 by MarketBeat.com Staff


Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2022. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information | RSS Feeds

© 2022 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research.